Article Text

Download PDFPDF
Current management of ovarian carcinosarcoma
  1. M. S. Mano,
  2. D. D. Rosa,
  3. E. Azambuja,
  4. G. Ismael,
  5. S. Braga,
  6. V. D'HONDT,
  7. M. Piccart and
  8. A. Awada
  1. Department of Medical Oncology, Institut Jules Bordet, Brussels, Belgium
  1. Address correspondence and reprint requests to: Max S. Mano, MD, Chef de Clinique Adjoint, Department of Medical Oncology, Institut Jules Bordet, Bd de Waterloo 125, 1000 Brussels, Belgium. Email: max.mano{at}


Ovarian carcinosarcomas (OCS), also known as malignant mixed müllerian tumors, are uncommon malignancies that carry a poor prognosis. The presentation of OCS is usually indistinguishable from that of epithelial ovarian cancer. Due to its low frequency, prospective trials have been difficult to perform, but there is evidence that OCS are sensitive to platinum-based chemotherapy. Recent studies have shown encouraging results with platinum–ifosfamide and platinum–taxane schedules, which are usually considered the treatment of choice. However, poor performance status at presentation is also a common problem, so that many patients may be unsuitable for combination chemotherapy but may still benefit from single-agent platinum or ifosfamide or, occasionally, from nonplatinum schedules such as ifosfamide plus paclitaxel. Aggressive cytoreductive surgery appears to have a positive impact on outcome and should probably be offered to most patients. However, this procedure has been associated with higher rates of complication in OCS and should only be attempted by experienced (gynecological) surgeons in centers with expertise in the management of gynecological malignancies

  • carcinosarcoma
  • female genital tract
  • chemotherapy
  • radiotherapy

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.